RxDoctor Payments Data

Andrea Smith, MD

Family Medicine · Travelers Rest, SCNPI 1619261393

Payments from drug & device makers

$900in general payments, 2019–2025

Across 46 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$195
  • Boehringer Ingelheim$130
  • GSK$121
  • Novo Nordisk$90
  • Merck$62
  • Amarin Pharma, Inc.$54
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900 in reported general payments places this provider in the 55th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$72,214
Medicare patients
177
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$207,430
JardianceEmpagliflozin166$205,864
TrulicityDulaglutide78$142,643
MounjaroTirzepatide64$124,451
FarxigaDapagliflozin Propanediol39$60,100
EliquisApixaban54$59,663
LinzessLinaclotide46$55,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$46,517
XareltoRivaroxaban42$36,034
TradjentaLinagliptin22$28,280
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$22,793
JanuviaSitagliptin Phosphate13$21,925
EntrestoSacubitril/Valsartan12$13,680
Varenicline Tartrate60$13,016
Tresiba Flextouch U-100Insulin Degludec28$12,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$48$267,094142 claims
Boehringer IngelheimJardiance, Tradjenta$130$234,145188 claims
Novo NordiskOzempic$90$207,430106 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$121$74,67682 claims
AstraZenecaFarxiga, Brilinta$25$71,50355 claims
PfizerEliquis, Lyrica$19$67,36166 claims
AbbVieLinzess$195$55,67146 claims
Johnson & JohnsonXarelto$13$36,03442 claims
MerckJanuvia$62$21,92513 claims
NovartisEntresto$19$13,68012 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$16$12,51911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Travelers Rest

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →